Trong nh\u1eefng l\u1ea7n \u0111\u1ea7u khi ti\u1ebfp x\u00fac v\u1edbi nh\u1eefng b\u00e0i b\u00e1o nghi\u00ean c\u1ee9u, m\u00ecnh ph\u1ea3i m\u1ea5t h\u00e0ng gi\u1edd \u0111\u1ed3ng h\u1ed3 \u0111\u1ec3 v\u1eeba \u0111\u1ecdc, v\u1eeba tra t\u1eeb \u0111i\u1ec3n c\u00e1c thu\u1eadt ng\u1eef n\u00e0y, v\u1eeba t\u00ecm c\u00e1c th\u00f4ng tin \u0111\u1ec3 hi\u1ec3u \u00fd ngh\u0129a c\u1ee7a ch\u00fang. <\/p>\n\n\n\n
Do \u0111\u00f3, hi v\u1ecdng b\u00e0i vi\u1ebft n\u00e0y s\u1ebd ti\u1ebft ki\u1ec7m cho b\u1ea1n th\u1eddi gian \u0111\u1ec3 \u0111\u1ecdc nghi\u00ean c\u1ee9u c\u0169ng nh\u01b0 hi\u1ec3u m\u1ed9t c\u00e1ch r\u00f5 r\u00e0ng t\u1eebng kh\u00e1i ni\u1ec7m qua nh\u1eefng v\u00ed d\u1ee5 minh h\u1ecda \u0111\u01b0\u1ee3c di\u1ec5n gi\u1ea3i theo c\u00e1ch \u0111\u01a1n gi\u1ea3n h\u00f3a nh\u1ea5t. V\u00ec c\u00f3 r\u1ea5t nhi\u1ec1u thu\u1eadt ng\u1eef n\u00ean m\u00ecnh s\u1ebd chia b\u00e0i vi\u1ebft n\u00e0y l\u00e0m 2 ph\u1ea7n. Ph\u1ea7n 1 s\u1ebd bao g\u1ed3m 31 thu\u1eadt ng\u1eef. <\/p>\n\n\n\n
N\u1ebfu b\u1ea1n c\u1ea7n b\u1ea3n word \u0111\u1ec3 tra c\u1ee9u thu\u1eadn ti\u1ec7n, vui l\u00f2ng share b\u00e0i vi\u1ebft t\u1ea1i Fanpage Th\u01b0\u01a1ng Library<\/a> \u1edf ch\u1ebf \u0111\u1ed9 c\u00f4ng khai v\u00e0 g\u1edfi inbox m\u00e0n h\u00ecnh t\u1ea1i Fanpage \u0111\u1ec3 c\u00f3 th\u1ec3 nh\u1eadn \u0111\u01b0\u1ee3c ph\u1ea7n 1 c\u1ee7a b\u00e0i vi\u1ebft. \u0110\u00e2y l\u00e0 c\u00e1ch h\u1ed7 tr\u1ee3 Th\u01b0\u01a1ng Library chia s\u1ebb th\u00eam th\u00f4ng tin t\u1edbi nhi\u1ec1u \u0111\u1ed9c gi\u1ea3 h\u01a1n. <\/p>\n\n\n\n M\u1ed9t thay \u0111\u1ed5i ti\u00eau c\u1ef1c ho\u1eb7c s\u1ef1 c\u1ed1 y t\u1ebf x\u1ea3y ra trong qu\u00e1 tr\u00ecnh th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng ho\u1eb7c trong m\u1ed9t kho\u1ea3ng th\u1eddi gian nh\u1ea5t \u0111\u1ecbnh sau khi k\u1ebft th\u00fac th\u1eed nghi\u1ec7m. Bi\u1ebfn c\u1ed1 ngo\u1ea1i \u00fd \u0111\u00f3 c\u00f3 th\u1ec3 c\u00f3 ho\u1eb7c kh\u00f4ng do ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb \u0111ang \u0111\u01b0\u1ee3c nghi\u00ean c\u1ee9u g\u00e2y ra1<\/sup><\/p>\n\n\n\n V\u00ed d\u1ee5:<\/strong> <\/p>\n\n\n\n B\u1ea1n b\u1ecb nh\u1ee9c \u0111\u1ea7u\/s\u1ed1t sau khi ti\u00eam vaccine Covid-19.<\/p>\n\n\n\n B\u1ea1n s\u1eed d\u1ee5ng thu\u1ed1c X \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb nh\u1ee9c \u0111\u1ea7u kinh ni\u00ean, sau 2 th\u00e1ng s\u1eed d\u1ee5ng, b\u1ea1n c\u1ea3m th\u1ea5y da h\u1ebft m\u1ee5n. \u0110\u00e2y c\u0169ng \u0111\u01b0\u1ee3c x\u1ebfp v\u00e0o bi\u1ebfn c\u1ed1 b\u1ea5t l\u1ee3i v\u00ec theo nh\u01b0 \u0111\u1ecbnh ngh\u0129a, bi\u1ebfn c\u1ed1 \u0111\u00f3 x\u1ea3y ra \u201cb\u1ea5t th\u01b0\u1eddng\u201d trong qu\u00e1 tr\u00ecnh b\u1ea1n \u0111i\u1ec1u tr\u1ecb v\u1edbi thu\u1ed1c X. Th\u00f4ng th\u01b0\u1eddng, \u1edf c\u00e1c n\u01b0\u1edbc c\u00f3 h\u1ec7 th\u1ed1ng y t\u1ebf ph\u00e1t tri\u1ec3n, ng\u01b0\u1eddi ta s\u1ebd y\u00eau c\u1ea7u b\u1ea1n ghi nh\u1eadn c\u00e1c adverse event \u0111\u1ec3 thu th\u1eadp d\u1eef li\u1ec7u li\u00ean quan \u0111\u1ebfn t\u00ednh an to\u00e0n c\u1ee7a thu\u1ed1c. <\/p>\n\n\n\n M\u1ed9t s\u1ef1 ki\u1ec7n b\u1ea5t l\u1ee3i \u0111e d\u1ecda \u0111\u1ebfn t\u00ednh m\u1ea1ng, c\u1ea7n ph\u1ea3i nh\u1eadp vi\u1ec7n ho\u1eb7c th\u1eddi gian n\u1eb1m vi\u1ec7n k\u00e9o d\u00e0i, d\u1eabn \u0111\u1ebfn m\u1ea5t kh\u1ea3 n\u0103ng li\u00ean t\u1ee5c ho\u1eb7c \u0111\u00e1ng k\u1ec3, g\u00e2y d\u1ecb t\u1eadt b\u1ea9m sinh, can thi\u1ec7p b\u1eaft bu\u1ed9c \u0111\u1ec3 ng\u0103n ng\u1eeba th\u01b0\u01a1ng t\u1ed5n ho\u1eb7c d\u1eabn \u0111\u1ebfn t\u1eed vong2<\/sup><\/p>\n\n\n\n V\u00ed d\u1ee5:<\/strong> <\/p>\n\n\n\n B\u1ea1n c\u00f3 th\u1ec3 tham kh\u1ea3o th\u1ea3m h\u1ecda Thalidomide \u0111\u1ec3 r\u00f5 h\u01a1n v\u1ec1 bi\u1ebfn c\u1ed1 b\u1ea5t l\u1ee3i nghi\u1ec7m tr\u1ecdng. <\/p>\n\n\n\n https:\/\/cand.com.vn\/Ho-so-mat\/Thalidomide—Tham-hoa-den-toi-nhat-lich-su-y-duoc-the-gioi-i305022\/<\/a><\/p>\n\n\n\n Vi\u1ec7c ch\u1ec9 \u0111\u1ecbnh m\u1ed9t nh\u00f3m ho\u1eb7c nh\u00f3m nh\u1ecf nh\u1eefng ng\u01b0\u1eddi tham gia th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng nh\u1eadn can thi\u1ec7p, ho\u1eb7c kh\u00f4ng can thi\u1ec7p, nh\u01b0 \u0111\u01b0\u1ee3c quy \u0111\u1ecbnh trong \u0111\u1ec1 c\u01b0\u01a1ng nghi\u00ean c\u1ee9u3<\/sup><\/p>\n\n\n\n Ng\u01b0\u1eddi X tham gia nghi\u00ean c\u1ee9u \u0111\u01b0\u1ee3c ph\u00e2n v\u00e0o nh\u00f3m can thi\u1ec7p (s\u1eed d\u1ee5ng thu\u1ed1c nghi\u00ean c\u1ee9u) => g\u1ecdi l\u00e0 nh\u00e1nh can thi\u1ec7p.<\/p>\n\n\n\n M\u1ed9t quy tr\u00ecnh (v\u00ed d\u1ee5: x\u00e9t nghi\u1ec7m m\u00e1u, qu\u00e9t, v.v.) \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng \u0111\u1ec3 t\u1ea1o d\u1eef li\u1ec7u theo y\u00eau c\u1ea7u c\u1ee7a th\u1eed nghi\u1ec7m.<\/p>\n\n\n\n Li\u1ec7u ph\u00e1p n\u1ec1n l\u00e0 lo\u1ea1i thu\u1ed1c hi\u1ec7n t\u1ea1i \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng th\u01b0\u1eddng xuy\u00ean nh\u01b0 m\u1ed9t ti\u00eau chu\u1ea9n ch\u0103m s\u00f3c cho m\u1ed9t t\u00ecnh tr\u1ea1ng \/ b\u1ec7nh c\u1ee5 th\u1ec3.<\/p>\n\n\n\n Trong \u0111i\u1ec1u tr\u1ecb t\u0103ng huy\u1ebft \u00e1p, c\u00e1c nh\u00f3m thu\u1ed1c ARB, ACEI, CCB, l\u1ee3i ti\u1ec3u \u0111\u01b0\u1ee3c xem nh\u01b0 c\u00e1c li\u1ec7u ph\u00e1p n\u1ec1n \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb kh\u1edfi \u0111\u1ea7u cho b\u1ec7nh nh\u00e2n. <\/p>\n\n\n\n M\u1ed9t lo\u1ea1i thi\u1ebft k\u1ebf th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng trong \u0111\u00f3 m\u1ed9t ho\u1eb7c nhi\u1ec1u b\u00ean li\u00ean quan \u0111\u1ebfn th\u1eed nghi\u1ec7m, ch\u1eb3ng h\u1ea1n nh\u01b0 nh\u00f3m nghi\u00ean c\u1ee9u ho\u1eb7c ng\u01b0\u1eddi tham gia, kh\u00f4ng bi\u1ebft ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb n\u00e0o \u0111\u00e3 \u0111\u01b0\u1ee3c ch\u1ec9 \u0111\u1ecbnh cho nh\u1eefng ng\u01b0\u1eddi tham gia n\u00e0o. Ph\u01b0\u01a1ng ph\u00e1p n\u00e0y nh\u1eb1m h\u1ea1n ch\u1ebf bias khi b\u1ec7nh nh\u00e2n v\u00e0 nh\u00e0 \u0111i\u1ec1u tr\u1ecb bi\u1ebft m\u00ecnh thu\u1ed9c nh\u00f3m n\u00e0o.<\/p>\n\n\n\n Nh\u00e3n m\u1edf (open-label):<\/strong> T\u1ea5t c\u1ea3 ng\u01b0\u1eddi tham gia \u0111\u1ec1u bi\u1ebft m\u00ecnh thu\u1ed9c nh\u00f3m n\u00e0o c\u1ee7a nghi\u00ean c\u1ee9u<\/p>\n\n\n\n M\u00f9 \u0111\u01a1n (Single blind<\/strong>): Ch\u1ec9 b\u1ec7nh nh\u00e2n kh\u00f4ng bi\u1ebft m\u00ecnh thu\u1ed9c nh\u00f3m n\u00e0o<\/p>\n\n\n\n M\u00f9 \u0111\u00f4i (Double blind):<\/strong> Trong m\u1ed9t th\u1eed nghi\u1ec7m m\u00f9 \u0111\u00f4i, ch\u1ec9 c\u00f3 nghi\u00ean c\u1ee9u vi\u00ean bi\u1ebft lo\u1ea1i thu\u1ed1c nghi\u00ean c\u1ee9u m\u00e0 ng\u01b0\u1eddi tham gia \u0111ang nh\u1eadn; nh\u1eefng ng\u01b0\u1eddi tham gia, b\u00e1c s\u0129, y t\u00e1 v\u00e0 nh\u00e2n vi\u00ean th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng kh\u00e1c kh\u00f4ng \u0111\u01b0\u1ee3c th\u00f4ng b\u00e1o..<\/p>\n\n\n\n M\u00f9 ba (triple blind<\/strong>): c\u1ea3 b\u1ec7nh nh\u00e2n, ng\u01b0\u1eddi th\u1ef1c hi\u1ec7n can thi\u1ec7p v\u00e0 ng\u01b0\u1eddi ph\u00e2n t\u00edch k\u1ebft qu\u1ea3 \u0111\u1ec1u kh\u00f4ng bi\u1ebft b\u1ec7nh nh\u00e2n thu\u1ed9c nh\u00f3m n\u00e0o<\/p>\n\n\n\n PROBE (Prospective Randomized Open Blinded Endpoint<\/strong>): \u00c1p d\u1ee5ng cho nh\u1eefng nghi\u00ean c\u1ee9u nh\u00e3n m\u1edf (open-label), ch\u1ec9 ng\u01b0\u1eddi ph\u00e2n t\u00edch k\u1ebft qu\u1ea3 kh\u00f4ng bi\u1ebft b\u1ec7nh nh\u00e2n thu\u1ed9c nh\u00f3m n\u00e0o.<\/p>\n\n\n\n Ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb d\u00f9ng \u0111\u1ec3 so s\u00e1nh, \u0111\u1ed1i ch\u1ee9ng v\u1edbi nh\u00f3m \u0111i\u1ec1u tr\u1ecb ho\u1eb7c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb \u201cti\u00eau chu\u1ea9n\u201d \u0111\u01b0\u1ee3c so s\u00e1nh v\u1edbi ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb nghi\u00ean c\u1ee9u.<\/p>\n\n\n\n Nh\u00f3m ch\u1ee9ng c\u00f3 th\u1ec3 l\u00e0 ng\u01b0\u1eddi kh\u1ecfe m\u1ea1nh, ng\u01b0\u1eddi kh\u00f4ng \u0111\u01b0\u1ee3c \u0111i\u1ec1u tr\u1ecb, ng\u01b0\u1eddi d\u00f9ng placebo, ng\u01b0\u1eddi d\u00f9ng ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb \u201cti\u00eau chu\u1ea9n\u201d trong th\u1ef1c h\u00e0nh hi\u1ec7n t\u1ea1i ho\u1eb7c c\u00e1c \u0111i\u1ec1u tr\u1ecb kh\u00e1c.<\/p>\n\n\n\n Nh\u00f3m \u0111i\u1ec1u tr\u1ecb<\/strong> (c\u00f2n g\u1ecdi l\u00e0 nh\u00f3m th\u1eed nghi\u1ec7m<\/strong> ) nh\u1eadn \u0111\u01b0\u1ee3c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb m\u00e0 nh\u00e0 nghi\u00ean c\u1ee9u quan t\u00e2m \u0111\u1ebfn t\u00e1c \u0111\u1ed9ng c\u1ee7a n\u00f3 \u0111\u1ebfn b\u1ec7nh nh\u00e2n6<\/sup><\/p>\n\n\n\n B\u1ea1n quan t\u00e2m \u0111\u1ebfn vi\u1ec7c li\u1ec7u sinh vi\u00ean \u0111\u1ea1i h\u1ecdc c\u00f3 ho\u1ea1t \u0111\u1ed9ng t\u1ed1t h\u01a1n \u1edf tr\u01b0\u1eddng hay kh\u00f4ng n\u1ebfu h\u1ecd \u0111\u01b0\u1ee3c tr\u1ea3 ti\u1ec1n cho th\u00e0nh t\u00edch c\u1ee7a m\u00ecnh. \u0110\u1ec3 ki\u1ec3m tra \u0111i\u1ec1u n\u00e0y, b\u1ea1n chia m\u1ed9t s\u1ed1 h\u1ecdc sinh th\u00e0nh c\u00e1c nh\u00f3m ch\u1ee9ng (control)<\/strong> v\u00e0 nh\u00f3m can thi\u1ec7p (experimental group)<\/strong><\/p>\n\n\n\n B\u1eb1ng c\u00e1ch so s\u00e1nh s\u1ef1 thay \u0111\u1ed5i trung b\u00ecnh v\u1ec1 \u0111i\u1ec3m c\u1ee7a h\u1ecd trong n\u0103m, b\u1ea1n c\u00f3 th\u1ec3 t\u00ecm hi\u1ec3u xem li\u1ec7u c\u00e1c khuy\u1ebfn kh\u00edch ti\u1ec1n t\u1ec7 c\u00f3 c\u1ea3i thi\u1ec7n th\u00e0nh t\u00edch c\u1ee7a tr\u01b0\u1eddng hay kh\u00f4ng.<\/p>\n\n\n\n1. Adverse Event \u2013 Bi\u1ebfn c\u1ed1 ngo\u1ea1i \u00fd<\/strong><\/h3>\n\n\n\n
2. Serious adverse event – S\u1ef1 ki\u1ec7n b\u1ea5t l\u1ee3i nghi\u00eam tr\u1ecdng<\/strong><\/h3>\n\n\n\n
3. Arm\/Arm assignment \u2013 Nh\u00e1nh nghi\u00ean c\u1ee9u\/Ch\u1ec9 \u0111\u1ecbnh nh\u00e1nh nghi\u00ean c\u1ee9u<\/strong><\/h3>\n\n\n\n
V\u00ed d\u1ee5: <\/strong><\/h3>\n\n\n\n
4. Assessment – \u0110\u00e1nh gi\u00e1<\/strong><\/h3>\n\n\n\n
5. Background therapy – Li\u1ec7u ph\u00e1p n\u1ec1n<\/strong><\/h3>\n\n\n\n
V\u00ed d<\/strong>\u1ee5: <\/h4>\n\n\n\n
6. Blinding<\/strong> \u2013 L\u00e0m m\u00f9<\/strong><\/h3>\n\n\n\n
C\u00e1c lo\u1ea1i blinding s\u1eed d\u1ee5ng trong nghi\u00ean c\u1ee9u bao g\u1ed3m4<\/sup><\/h4>\n\n\n\n
7. Control \u2013 Nh\u00f3m ch\u1ee9ng<\/strong><\/h3>\n\n\n\n
8. Treatment group\/ Experimental group \u2013 Nh\u00f3m \u0111i\u1ec1u tr\u1ecb\/Nh\u00f3m can thi\u1ec7p<\/strong><\/h3>\n\n\n\n
V\u00ed d\u1ee5<\/strong>: <\/strong><\/strong><\/h3>\n\n\n\n
9. Clinical study\/<\/strong> International Study – Nghi\u00ean c\u1ee9u l\u00e2m s\u00e0ng 3<\/sup><\/strong><\/h3>\n\n\n\n